Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMCR
stocks logo

IMCR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
107.82M
+28.28%
-0.240
-241.16%
110.68M
+17.89%
-0.188
-59.96%
113.35M
+15.71%
-0.106
-205.71%
Estimates Revision
The market is revising Upward the revenue expectations for Immunocore Holdings plc (IMCR) for FY2025, with the revenue forecasts being adjusted by 1.35% over the past three months. During the same period, the stock price has changed by 8.10%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-54.55%
In Past 3 Month
Stock Price
Go Up
up Image
+8.10%
In Past 3 Month
Wall Street analysts forecast IMCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMCR is 63.33 USD with a low forecast of 36.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast IMCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMCR is 63.33 USD with a low forecast of 36.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 40.215
sliders
Low
36.00
Averages
63.33
High
100.00
Current: 40.215
sliders
Low
36.00
Averages
63.33
High
100.00
Mizuho
Graig Suvannavejh
Neutral
maintain
$36 -> $37
2025-11-10
Reason
Mizuho
Graig Suvannavejh
Price Target
$36 -> $37
2025-11-10
maintain
Neutral
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on Immunocore to $37 from $36 and keeps a Neutral rating on the shares following the Q3 report.
Morgan Stanley
Sean Laaman
Equal Weight
maintain
$34 -> $36
2025-11-10
Reason
Morgan Stanley
Sean Laaman
Price Target
$34 -> $36
2025-11-10
maintain
Equal Weight
Reason
Morgan Stanley analyst Sean Laaman raised the firm's price target on Immunocore to $36 from $34 and keeps an Equal Weight rating on the shares.
Wells Fargo
Eva Fortea Verdejo
Overweight
initiated
$60
2025-10-31
Reason
Wells Fargo
Eva Fortea Verdejo
Price Target
$60
2025-10-31
initiated
Overweight
Reason
Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Immunocore with an Overweight rating and $60 price target. The firm believes Kimmtrak "provides a good floor value" for the stock and indication expansion opportunities could offer upside over the next 12 months. There is room for further penetration, especially in the community setting, the analyst tells investors in a research note.
Guggenheim
Neutral
initiated
2025-09-17
Reason
Guggenheim
Price Target
2025-09-17
initiated
Neutral
Reason
Guggenheim assumed coverage of Immunocore with a Neutral rating. The company is a pioneer of the TCR therapeutics category with a solid commercial foundation in Kimmtrak - the only FDA approved systemic therapy for metastatic uveal melanoma and a $400M drug which has consistently topped the Street expectations since its launch in 2022, the analyst tells investors in a research note. Looking ahead to the next leg of growth however, the firm sees fewer sources of commercial outperformance for Kimmtrak as U.S. mUM market penetration continues to plateau, contributions from new ex-US launches taper, and real-world duration of therapy is fully appreciated, Guggenheim added.
Deutsche Bank
initiated
$65
2025-05-27
Reason
Deutsche Bank
Price Target
$65
2025-05-27
initiated
Reason
Oppenheimer
Oppenheimer
Outperform
maintain
$85 -> $86
2025-05-08
Reason
Oppenheimer
Oppenheimer
Price Target
$85 -> $86
2025-05-08
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Immunocore to $86 from $85 and keeps an Outperform rating on the shares. The firm notes that on Wednesday, the company announced strong Q1 sales for KIMMTRAK, with revenue of $93.9M vs. OPCO/Consensus of $88M/$87M, +12% from the prior quarter.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunocore Holdings PLC (IMCR.O) is -82.14, compared to its 5-year average forward P/E of -45.33. For a more detailed relative valuation and DCF analysis to assess Immunocore Holdings PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-45.33
Current PE
-82.14
Overvalued PE
17.15
Undervalued PE
-107.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-57.38
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
80.70
Undervalued EV/EBITDA
-195.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
15.55
Current PS
0.00
Overvalued PS
31.23
Undervalued PS
-0.12
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

IMCR News & Events

Events Timeline

(ET)
2025-11-07
08:08:38
Immunocore Reveals Phase 1 Results for Hepatitis B Candidate at AASLD
select
2025-11-06 (ET)
2025-11-06
07:14:55
Immunocore Announces Q3 Earnings Per Share of 0c, Falling Short of Consensus Estimate of 24c
select
2025-08-07 (ET)
2025-08-07
07:18:20
Immunocore reports Q2 EPS (20c), consensus (21c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-10Newsfilter
Immunocore to Showcase at Upcoming Investor Events

  • Company Overview: Immunocore Holdings plc is a biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, utilizing its ImmTAX platform for TCR bispecific immunotherapies.

  • Upcoming Conferences: The company will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, and the Jefferies London Healthcare Conference on November 19, 2025, with live webcasts available on their website.

  • Product Highlight: Immunocore's leading oncology therapy, KIMMTRAK, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several countries, including the US and EU.

  • Contact Information: For inquiries, Immunocore provides contact details for communications and investor relations, including email addresses and phone numbers.

[object Object]
Preview
4.0
10-23Benzinga
HC Wainwright & Co. Affirms Buy Rating for Immunocore Holdings, Keeps $100 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

[object Object]
Preview
4.0
10-21Yahoo Finance
H.C. Wainwright Maintains Positive Outlook on Immunocore Holdings plc (IMCR)

  • Analyst Ratings: Immunocore Holdings plc (NASDAQ: IMCR) received a Buy rating from H.C. Wainwright with a price target of $100, while Guggenheim initiated a Neutral rating, citing limited commercial growth potential for its drug KIMMTRAK.

  • Product Overview: Immunocore is a biotechnology company specializing in TCR bispecific immunotherapies, with KIMMTRAK as its lead product for treating metastatic uveal melanoma, and a diverse pipeline of additional therapies in development.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Immunocore Holdings PLC (IMCR) stock price today?

The current price of IMCR is 40.215 USD — it has increased 6.16 % in the last trading day.

arrow icon

What is Immunocore Holdings PLC (IMCR)'s business?

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

arrow icon

What is the price predicton of IMCR Stock?

Wall Street analysts forecast IMCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMCR is 63.33 USD with a low forecast of 36.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Immunocore Holdings PLC (IMCR)'s revenue for the last quarter?

Immunocore Holdings PLC revenue for the last quarter amounts to 103.69M USD, increased 29.22 % YoY.

arrow icon

What is Immunocore Holdings PLC (IMCR)'s earnings per share (EPS) for the last quarter?

Immunocore Holdings PLC. EPS for the last quarter amounts to -0.00 USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Immunocore Holdings PLC (IMCR)'s fundamentals?

The market is revising Upward the revenue expectations for Immunocore Holdings plc (IMCR) for FY2025, with the revenue forecasts being adjusted by 1.35% over the past three months. During the same period, the stock price has changed by 8.10%.
arrow icon

How many employees does Immunocore Holdings PLC (IMCR). have?

Immunocore Holdings PLC (IMCR) has 493 emplpoyees as of December 05 2025.

arrow icon

What is Immunocore Holdings PLC (IMCR) market cap?

Today IMCR has the market capitalization of 2.03B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free